| 1 |
diabetes mellitus type 2
(234 times)
|
Medicine
(53 times)
|
CVD (20 times)
BMI (17 times)
IR (8 times)
|
1999 Potential interactions of zinc in the neuroendocrine-endocrine disturbances of diabetes mellitus type 2.
|
| 2 |
DM type 2
(12 times)
|
Neurology
(6 times)
|
DM (10 times)
DM1 (6 times)
AGA (1 time)
|
2005 Hyper-CK-emia as the sole manifestation of myotonic dystrophy type 2.
|
| 3 |
myotonic dystrophy type 2
(10 times)
|
Neurology
(5 times)
|
FXTAS (2 times)
SCA8 (2 times)
HDL2 (1 time)
|
2002 Dominantly inherited, non-coding microsatellite expansion disorders.
|
| 4 |
disorders in myotonic dystrophy type 2
(5 times)
|
Neurology
(4 times)
|
DM1 (3 times)
EDS (3 times)
RLS (2 times)
|
2004 Myotonic dystrophy: RNA pathogenesis comes into focus.
|
| 5 |
development and in myotonic dystrophy type 2
(3 times)
|
Biochemistry
(2 times)
|
sIBM (3 times)
CNBP (2 times)
CD (1 time)
|
2010 CNBP: a multifunctional nucleic acid chaperone involved in cell death and proliferation control.
|
| 6 |
diagnosed for Myotonic Dystrophy type 2
(3 times)
|
Molecular Biology
(1 time)
|
TP-PCR (1 time)
|
2010 Validation of sensitivity and specificity of tetraplet-primed PCR (TP-PCR) in the molecular diagnosis of myotonic dystrophy type 2 (DM2).
|
| 7 |
DMPK, while myotonic dystrophy type 2
(3 times)
|
Biophysics
(1 time)
|
DM (3 times)
|
2013 Clinical aspects, molecular pathomechanisms and management of myotonic dystrophies.
|
| 8 |
decreased in erythrocytes of humans with type 2 diabetes
(2 times)
|
Biology
(1 time)
|
DMPC (1 time)
NO (1 time)
PDE3 (1 time)
|
2006 Expression of the heterotrimeric G protein Gi and ATP release are impaired in erythrocytes of humans with diabetes mellitus.
|
| 9 |
development of type 2 diabetes
(2 times)
|
Medicine
(1 time)
|
AD (1 time)
DMN (1 time)
FMD (1 time)
|
2005 Liver alanine aminotransferase, insulin resistance and endothelial dysfunction in normotriglyceridaemic subjects with type 2 diabetes mellitus.
|
| 10 |
disease called myotonic dystrophy type 2
(2 times)
|
Biochemistry
(1 time)
|
FECD (1 time)
IR (1 time)
NMR (1 time)
|
2011 The origin of genetic instability in CCTG repeats.
|
| 11 |
dyslipidaemia and type 2 diabetes
(2 times)
|
Urology
(1 time)
|
CV (1 time)
FGF21 (1 time)
WC (1 time)
|
2012 Central obesity as measured by waist circumference is predictive of severity of lower urinary tract symptoms.
|
| 12 |
dystrophy locus, myotonic dystrophy type 2
(2 times)
|
Genetics, Medical
(1 time)
|
DM (1 time)
DMPK (1 time)
PDM (1 time)
|
1998 Genetic mapping of a second myotonic dystrophy locus.
|
| 13 |
2-diabetes mellitus
(1 time)
|
Medicine
(1 time)
|
MDA (1 time)
|
2000 [Plasma malondialdehyde in patients with type 2 diabetes mellitus and in patients with coronary disease].
|
| 14 |
D virus M2 protein
(1 time)
|
Medicine
(1 time)
|
CM2 (1 time)
TEVC (1 time)
|
2018 Influenza D virus M2 protein exhibits ion channel activity in Xenopus laevis oocytes.
|
| 15 |
daily arterial stiffness parameters in patients with type 2 diabetes
(1 time)
|
Neurology
(1 time)
|
AAI (1 time)
CAN (1 time)
LC (1 time)
|
2015 [The effect of long-chain polyunsaturated omega-3 fatty acids on the arterial stiffness parameters in patients with diabetes mellitus type 2 and cardiovascular autonomic neuropathy].
|
| 16 |
damage Type 2 Diabetes
(1 time)
|
|
---
|
2016 Confronting Complacency in the Face of Calamity: Mobilizing for the Home Front War against Diabetes.
|
| 17 |
DANGEROUS MIX2
(1 time)
|
Biology
(1 time)
|
NLR (1 time)
TIR (1 time)
|
2017 Activation of a Plant NLR Complex through Heteromeric Association with an Autoimmune Risk Variant of Another NLR.
|
| 18 |
data for myotonic dystrophy type 2
(1 time)
|
Neurology
(1 time)
|
BMC (1 time)
DEXA (1 time)
DM1 (1 time)
|
2019 Body composition analysis in patients with myotonic dystrophy types 1 and 2.
|
| 19 |
Data manager 2
(1 time)
|
Biochemistry
(1 time)
|
AMR (1 time)
TAT (1 time)
WTE (1 time)
|
2018 Designing and evaluating autoverification rules for thyroid function profiles and sex hormone tests.
|
| 20 |
define remission of type 2 diabetes
(1 time)
|
|
ADA (1 time)
|
2017 Variations in diabetes remission rates after bariatric surgery in Spanish adults according to the use of different diagnostic criteria for diabetes.
|
| 21 |
degree of control of the hypercholesterolaemia of type-2 diabetic
(1 time)
|
Primary Health Care
(1 time)
|
---
|
2000 [Cost analysis and degree of hypercholesterolemia control in type 2 diabetic patients according to different groups and scientific societies].
|
| 22 |
demonstrate, using type 2 diabetes
(1 time)
|
Medicine
(1 time)
|
---
|
2010 MicroRNA-integrated and network-embedded gene selection with diffusion distance.
|
| 23 |
Depression is a common complication in type 2 diabetes
(1 time)
|
Psychiatry
(1 time)
|
DIF (1 time)
EDS (1 time)
|
2011 Dimensionality and scale properties of the Edinburgh Depression Scale (EDS) in patients with type 2 diabetes mellitus: the DiaDDzoB study.
|
| 24 |
Depression is common in patients with diabetes type 2
(1 time)
|
Primary Health Care
(1 time)
|
CHD (1 time)
PHQ-9 (1 time)
Step-Dep (1 time)
|
2017 Process evaluation of a stepped-care program to prevent depression in primary care: patients' and practice nurses' experiences.
|
| 25 |
depression is common in patients with type 2 diabetes
(1 time)
|
Primary Health Care
(1 time)
|
CHD (1 time)
PNs (1 time)
|
2018 Patients' and practice nurses' perceptions of depression in patients with type 2diabetes and/or coronary heart disease screened for subthreshold depression.
|
| 26 |
determine the association of metabolic diseases, particularly diabetes type 2
(1 time)
|
Neoplasms
(1 time)
|
HT (1 time)
HUSM (1 time)
|
2008 Association of colorectal carcinoma with metabolic diseases; experience with 138 cases from Kelantan, Malaysia.
|
| 27 |
determine the effects of Type 2 diabetes
(1 time)
|
Neurology
(1 time)
|
---
|
2017 Cognitive deficits in non-demented diabetic elderly appear independent of brain amyloidosis.
|
| 28 |
determine whether the management of type 2 diabetes
(1 time)
|
Internal Medicine
(1 time)
|
NSD (1 time)
|
2009 Diabetes specialist nurse as main care provider for patients with type 2 diabetes.
|
| 29 |
development of cardiovascular dysfunction in type 2 diabetes
(1 time)
|
Medicine
(1 time)
|
---
|
2013 Cardioprotective properties of omentin-1 in type 2 diabetes: evidence from clinical and in vitro studies.
|
| 30 |
development of foot ulcers in patients with type 2 diabetes
(1 time)
|
Medicine
(1 time)
|
DMD (1 time)
|
2009 [Foot ulceration risk factors in type 2 diabetes mellitus].
|
| 31 |
diabetes mellitus of 2nd type
(1 time)
|
Medicine
(1 time)
|
CHD (1 time)
NAFLD (1 time)
|
2013 [Additional advantages of mexicor used in combined therapy of coronary heat disease and diabetes mellitus of 2nd type].
|
| 32 |
diabetic men, we evaluated 11 men with type 2 diabetes
(1 time)
|
Biotechnology
(1 time)
|
BRS (1 time)
CPET (1 time)
LED (1 time)
|
2020 Acute effect of photobiomodulation using light-emitting diodes (LEDs) on baroreflex sensitivity during and after constant loading exercise in patients with type 2 diabetes mellitus.
|
| 33 |
diets in the primary-care management of type 2 diabetic
(1 time)
|
Diabetes Mellitus
(1 time)
|
KD (1 time)
|
2019 Optimizing glycemic control in type 2 diabetic patients through the use of a low-carbohydrate, high-fat, ketogenic diet: a review of two patients in primary care.
|
| 34 |
discovered gene locus of myotonic dystrophy type 2
(1 time)
|
Neurology
(1 time)
|
PROMM (1 time)
|
1999 Linkage of proximal myotonic myopathy to chromosome 3q.
|
| 35 |
discrimination on the continuity of Type 2 Diabetes
(1 time)
|
Medicine
(1 time)
|
---
|
2016 [Healthcare mistreatment attributed to discrimination among mapuche patients and discontinuation of diabetes care].
|
| 36 |
disease'; and (2) myotonic dystrophy type 2
(1 time)
|
Neurology
(1 time)
|
DM1 (1 time)
|
2010 The myotonic dystrophies: diagnosis and management.
|
| 37 |
diseased controls with myotonic dystrophy type 2
(1 time)
|
|
ALS (1 time)
BPI (1 time)
|
2015 Characteristics of pain in amyotrophic lateral sclerosis.
|
| 38 |
Disturbed glucose metabolism, particularly in diabetes type 2
(1 time)
|
Geriatrics
(1 time)
|
AGE (1 time)
CM (1 time)
LF (1 time)
|
2013 Advanced glycation end products and lipofuscin deposits share the same location in cardiocytes of the failing heart.
|
| 39 |
DM of type 2
(1 time)
|
Medicine
(1 time)
|
DM (1 time)
DM1 (1 time)
|
2008 Repeat length and RNA expression level are not primary determinants in CUG expansion toxicity in Drosophila models.
|
| 40 |
DM type 2 model
(1 time)
|
Cell Biology
(1 time)
|
DM (1 time)
PTCs (1 time)
TEM (1 time)
|
2018 Reabsorption in the proximal tubuli-ultrastructural evidence for a novel aspect of renal VEGF trafficking.
|
| 41 |
DM1 and myotonic dystrophy type 2
(1 time)
|
Molecular Biology
(1 time)
|
CUGBP1 (1 time)
MBNL1 (1 time)
NCAM (1 time)
|
2010 Analysis of MTMR1 expression and correlation with muscle pathological features in juvenile/adult onset myotonic dystrophy type 1 (DM1) and in myotonic dystrophy type 2 (DM2).
|
| 42 |
DM2 group
(1 time)
|
Andrology
(1 time)
|
BE2 (1 time)
BT (1 time)
CG (1 time)
|
2014 Evaluation of the hypothalamic-pituitary-gonadal axis in eugonadal men with type 2 diabetes mellitus.
|
| 43 |
DM2-CAD group
(1 time)
|
Genetics, Medical
(1 time)
|
CAD (1 time)
ROC (1 time)
|
2019 Circulating miR-130 and its target PPAR-gamma may be potential biomarkers in patients of coronary artery disease with type 2 diabetes mellitus.
|
| 44 |
DM2-LDL
(1 time)
|
Endocrinology
(1 time)
|
Ang II (1 time)
IGT-LDL (1 time)
LDL (1 time)
|
2009 Prediabetic and diabetic in vivo modification of circulating low-density lipoprotein attenuates its stimulatory effect on adrenal aldosterone and cortisol secretion.
|
| 45 |
Drosophila model of myotonic dystrophy type 2
(1 time)
|
Medicine
(1 time)
|
CELF1 (1 time)
|
2017 (CCUG)n RNA toxicity in a Drosophila model of myotonic dystrophy type 2 (DM2) activates apoptosis.
|
| 46 |
dyslipidemia is particularly common in people with type 2 diabetes
(1 time)
|
Ophthalmology
(1 time)
|
DR (1 time)
P/L (1 time)
PDW (1 time)
|
2016 The association of hematologic inflammatory markers with atherogenic index in type 2 diabetic retinopathy patients.
|
| 47 |
dystrophia myotonica type 2
(1 time)
|
Genetics, Medical
(1 time)
|
DM (1 time)
DM1 (1 time)
|
2004 Insulin receptor splicing alteration in myotonic dystrophy type 2.
|
| 48 |
dystrophies in adulthood; however, myotonic dystrophy type 2
(1 time)
|
Neurology
(1 time)
|
NMDs (1 time)
PROs (1 time)
|
2018 Towards clinical outcome measures in myotonic dystrophy type 2: a systematic review.
|
| 49 |
dystrophy: higher than expected frequency of myotonic dystrophy type 2
(1 time)
|
Genetics, Medical
(1 time)
|
DM (1 time)
NMD (1 time)
|
2011 Population frequency of myotonic dystrophy: higher than expected frequency of myotonic dystrophy type 2 (DM2) mutation in Finland.
|
| 50 |
type-2-diabetes mellitus
(1 time)
|
Biochemistry
(1 time)
|
---
|
2012 Relationship of fetuin-A levels to weight-dependent insulin resistance and type 2 diabetes mellitus.
|
A Search Service for Abbreviation / Long Form